Since its discovery in 1977, DSIP has transitioned from being viewed strictly as a somnogenic (sleep-inducing) agent to a multifaceted neuromodulator with significant implications in neuroendocrinology and stress adaptation
Still, these data were deemed insufficient by health authorities in Japan for approval of ultrahigh-dose methylcobalamin for treating people with ALS, leading Eisai to withdraw its regulatory application in 2016
Members access evidence-based protocols for immune-modulating peptides, detailed safety guides for autoimmune-specific considerations, dosing calculators tailored to individual needs, and a community of researchers navigating the complex intersection of peptide science and autoimmune disease management
Ensuring adequate sleep duration, maintaining consistent sleep schedules, and addressing sleep quality issues supports the healing BPC-157 promotes
(PubMed) Zhang C, Luo J, Yuan C, Ding D